Meningitis - Pipeline Review, H1 2020
Meningitis - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H1 2020, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.
"Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening.Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis.
Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B.
This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximatiely 44-46% cases of bacterial meningitis have all of the following three symptoms - severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If nove of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely.Other clinical feature include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby’s head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis."
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 4, 5 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.
Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H1 2020, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.
"Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening.Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis.
Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B.
This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximatiely 44-46% cases of bacterial meningitis have all of the following three symptoms - severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If nove of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely.Other clinical feature include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby’s head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis."
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 4, 5 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.
Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Meningitis - Overview
Meningitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Meningitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meningitis - Companies Involved in Therapeutics Development
CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
Eubiologics Co Ltd
FUJIFILM Toyama Chemical Co Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Linnaeus Bioscience Inc
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Olymvax Biopharmaceuticals Inc
Pneumagen Ltd
TGV Therapeutics
Yisheng Biopharma Co Ltd
Meningitis - Drug Profiles
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae type b + rotavirus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSB-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EUC-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flucytosine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A and C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYC-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neumifil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal [serotype 4, 6A] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GWT1 for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-2307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1129 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1598 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Meningitis - Dormant Projects
Meningitis - Discontinued Products
Meningitis - Product Development Milestones
Featured News & Press Releases
Feb 19, 2020: Matinas BioPharma announces DSMB approval to commence part 2 of EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis
Oct 14, 2019: Matinas BioPharma initiates EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of fungal cryptococcal meningitis
Oct 07, 2019: Matinas BioPharma receives orphan drug designation from U.S. FDA for MAT2203 for the treatment of cryptococcosis
Jul 25, 2019: Matinas BioPharma receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
Jun 03, 2019: Matinas BioPharma to present on MAT2203 at the 9th Annual LD Micro Invitational
May 28, 2019: Matinas BioPharma announces publication of MAT2203 Preclinical Cryptococcal Meningitis data in the American Society for Microbiology Journal, mBio
May 01, 2019: Matinas BioPharma selected to present at the BioNJ Ninth Annual BioPartnering Conference
Dec 20, 2018: Matinas BioPharma to present data on MAT2203 at Biotech Showcase 2019
Aug 08, 2017: Matinas BioPharma Reaffirms Clinical and Regulatory Strategy to Advance MAT2203
Jun 02, 2017: Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
May 30, 2017: Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology's ASM Microbe 2017 Conference
Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated
Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis
Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis
Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Meningitis - Overview
Meningitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Meningitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meningitis - Companies Involved in Therapeutics Development
CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
Eubiologics Co Ltd
FUJIFILM Toyama Chemical Co Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Linnaeus Bioscience Inc
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Olymvax Biopharmaceuticals Inc
Pneumagen Ltd
TGV Therapeutics
Yisheng Biopharma Co Ltd
Meningitis - Drug Profiles
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae type b + rotavirus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSB-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EUC-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flucytosine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A and C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYC-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neumifil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal [serotype 4, 6A] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GWT1 for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-2307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1129 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1598 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Meningitis - Dormant Projects
Meningitis - Discontinued Products
Meningitis - Product Development Milestones
Featured News & Press Releases
Feb 19, 2020: Matinas BioPharma announces DSMB approval to commence part 2 of EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis
Oct 14, 2019: Matinas BioPharma initiates EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of fungal cryptococcal meningitis
Oct 07, 2019: Matinas BioPharma receives orphan drug designation from U.S. FDA for MAT2203 for the treatment of cryptococcosis
Jul 25, 2019: Matinas BioPharma receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
Jun 03, 2019: Matinas BioPharma to present on MAT2203 at the 9th Annual LD Micro Invitational
May 28, 2019: Matinas BioPharma announces publication of MAT2203 Preclinical Cryptococcal Meningitis data in the American Society for Microbiology Journal, mBio
May 01, 2019: Matinas BioPharma selected to present at the BioNJ Ninth Annual BioPartnering Conference
Dec 20, 2018: Matinas BioPharma to present data on MAT2203 at Biotech Showcase 2019
Aug 08, 2017: Matinas BioPharma Reaffirms Clinical and Regulatory Strategy to Advance MAT2203
Jun 02, 2017: Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
May 30, 2017: Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology's ASM Microbe 2017 Conference
Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated
Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis
Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis
Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Meningitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Meningitis - Pipeline by CanSino Biologics Inc, H1 2020
Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Meningitis - Pipeline by Eubiologics Co Ltd, H1 2020
Meningitis - Pipeline by FUJIFILM Toyama Chemical Co Ltd, H1 2020
Meningitis - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, H1 2020
Meningitis - Pipeline by Linnaeus Bioscience Inc, H1 2020
Meningitis - Pipeline by Matinas BioPharma Holdings Inc, H1 2020
Meningitis - Pipeline by Mycovia Pharmaceuticals Inc, H1 2020
Meningitis - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020
Meningitis - Pipeline by Pneumagen Ltd, H1 2020
Meningitis - Pipeline by TGV Therapeutics, H1 2020
Meningitis - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
Meningitis - Dormant Projects, H1 2020
Meningitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Meningitis - Discontinued Products, H1 2020
Number of Products under Development for Meningitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Meningitis - Pipeline by CanSino Biologics Inc, H1 2020
Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Meningitis - Pipeline by Eubiologics Co Ltd, H1 2020
Meningitis - Pipeline by FUJIFILM Toyama Chemical Co Ltd, H1 2020
Meningitis - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, H1 2020
Meningitis - Pipeline by Linnaeus Bioscience Inc, H1 2020
Meningitis - Pipeline by Matinas BioPharma Holdings Inc, H1 2020
Meningitis - Pipeline by Mycovia Pharmaceuticals Inc, H1 2020
Meningitis - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020
Meningitis - Pipeline by Pneumagen Ltd, H1 2020
Meningitis - Pipeline by TGV Therapeutics, H1 2020
Meningitis - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
Meningitis - Dormant Projects, H1 2020
Meningitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Meningitis - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Meningitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
Eubiologics Co Ltd
FUJIFILM Toyama Chemical Co Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Linnaeus Bioscience Inc
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Olymvax Biopharmaceuticals Inc
Pneumagen Ltd
TGV Therapeutics
Yisheng Biopharma Co Ltd
Number of Products under Development for Meningitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
Eubiologics Co Ltd
FUJIFILM Toyama Chemical Co Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Linnaeus Bioscience Inc
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Olymvax Biopharmaceuticals Inc
Pneumagen Ltd
TGV Therapeutics
Yisheng Biopharma Co Ltd
